Background
==========

Lung cancer constitutes one of the malignancies with the greatest incidence and mortality rates with 1.6 million new cases and 1.4 million deaths each year \[[@B1],[@B2]\]. Although initial use of platin-based cytotoxic chemotherapy improved the overall survival rate and life quality of the patients, the outcome remains poor due to deleterious development of drug resistance resulting in less than 15% lung cancer patients surviving for at least five years \[[@B2],[@B3]\]. Approximately 80 - 85% of the lung cancer patients are diagnosed with an advanced stage of non-small cell lung cancer (NSCLC) that has limited therapeutic options due to metastasis \[[@B1],[@B4],[@B5]\] and among the three types of NSCLC, patients identified with squamous carcinoma which involves lymph node metastasis accounts for 60% \[[@B5],[@B6]\]. In the advance stage of NSCLC, surgery is not possible to remove all apparent lesions hence leading to the high rate of cancer recurrence \[[@B7]\]. Therefore, lethality of lung cancer is often attributed to late diagnosis, metastasis, and the occurrence of drug resistance \[[@B8]\]. Thus, the development of an efficient cancer diagnostic method is crucial since an early detection of cancer while it is still localized and curable is one of the most promising approaches to reduce increasing cancer burden \[[@B9]\]. This requires an understanding of the pathophysiology of the disease \[[@B10],[@B11]\] which can be made possible via proteomic studies. Cancer proteomics allow the screening of early diagnostic markers or potential drug targets \[[@B6]\] by comparing the proteomes of the diseased and diseased-treated samples that allows identification of aberrantly expressed proteins \[[@B5],[@B10]\]. These proteins could be biomarker candidates to expedite non-invasive diagnosis of early-stage malignant tumor, as well as to aid the monitoring of tumor progression and therapy effectiveness \[[@B12]\]. Similar to other malignant pathologies, tumor markers for NSCLC remained inadequate. Serum biomarkers employed in the current clinical setting such as ENO (enolase alpha), CEA (carcinoembryonic antigen), SCC (squamous cell carcinoma), CA-125 (cancer antigen 125) or TPA (tissue polypeptide antigen) are not satisfactory due to their low sensitivity and specificity \[[@B13],[@B14]\]. In the quest for novel diagnostic or prognostic biomarkers, the proteomic technique is ideal since it permits qualitative and quantitative analysis of numerous proteins simultaneously \[[@B9],[@B13]\]. Moreover, the search for biomarkers at the protein level is more dependable than at the transcriptional level as protein expression may not necessarily associate with mRNA expression \[[@B14]\].

Natural-product based drugs are gaining their popularity as preventive medicines or for health management, and hence this has spurred an intensive search for bioactive plant-derived anticancer compounds \[[@B15]\]. The genus *Phyllanthus* is one of the most widely distributed plants throughout the Amazon rainforests as well as other tropical and subtropical regions. Abundant studies on *Phyllanthus spp*. started in the late 1980′s when the clinical efficacy of *Phyllanthus niruri* against viral Hepatitis B was observed \[[@B16]\]. Various therapeutic actions of this genus have been reported, including being antihepatotoxic, antilithic, antihypertensive, anticarcinogenic, and most recently anti-HIV as well \[[@B16]-[@B19]\]. We have demonstrated antimetastatic and antiproliferative activities of *Phyllanthus* against several metastatic cell lines such as lung carcinoma (A549), breast (MCF-7) carcinomas \[[@B17]\], melanoma (MeWo), as well as prostate (PC-3) carcinoma \[[@B20]\].

Nevertheless, the exact mechanisms for the antimetastatic activities of *Phyllanthus* are still uncertain. MAP kinase (MAPK) is one of the signaling pathways known to mediate metastasis via transmission of extracellular stimuli into the nucleus that activate the serine/threonine kinases which belong to the MAPK superfamily \[[@B21]\]. MAPK serine/threonine superfamily is made up of three well-described subgroups, including ERK1/2 or p44/42 MAPK, JNK/SAPK, and p38 MAPK. These diverse pathways with distinct downstream targets are activated by various stimuli to regulate cell proliferation, apoptosis, and metastasis \[[@B21],[@B22]\]. Regulation of metastasis by MAPK is mainly via controlling the cells' expression of matrix metalloproteinases (MMPs) enzymes by decreasing the nuclear levels of NFκB, c-Fos, or c-Jun \[[@B21],[@B22]\]. The MMPs are a family of at least 20 members of highly homologous, zinc- and calcium-dependent endopeptidases which can degrade virtually all extracellular matrix (ECM) components \[[@B23]\]. Among these MMPs, MMP2 and MMP9 are abundantly expressed, secreted, and activated in various malignant tumors \[[@B22],[@B24]\]. Recent studies also shown that MMP7 plays an essential role in ectodomain shedding of cell-surface molecules such as EGFR, HB-EGF, Fas ligand, and E-cadherin in addition to its ability to degrade ECM components. Therefore, these enzymes are the most vital ones implicated in cancer invasion and metastasis \[[@B24],[@B25]\].

Hypoxia pathway is another chief regulator of metastatic process. Hypoxia-inducible factor-1 (HIF-1) is the determining factor for oxygen-dependent gene regulation and is a dimer of HIF-1α and HIF-1β. Its regulation is mainly governed by the transactivation and stabilization of HIF-1α protein resided in the cytoplasm \[[@B26]\]. Under normoxia condition, HIF-1α instantaneously interacts with von Hipple--Lindau (pVHL) ubiquitin E3 ligase complex and is targeted for proteasomal degradation due to hydroxylation of two specific proline residues within the oxygen-dependent degradation domain by prolyl hydroxylases \[[@B7],[@B26]\]. Contrarily, HIF-1α will be stabilized with increased expression during hypoxic condition, allowing it to translocate into the nucleus and dimerize with HIF-1β. HIF-1 will subsequently bind to the hypoxia response elements to regulate transcription of over 100 target genes which favors tumor growth and metastasis, including vascular endothelial growth factor (VEGF) as well as genes that regulate cellular processes such as energy metabolism, cell proliferation, vascular development and remodelling, as well as vasotone \[[@B2],[@B7],[@B26]\].

In our previous study, *Phyllanthus* extracts were shown to inhibit A549 (lung carcinoma) cells growth with IC~50~ values ranging from 60--130 μg/ml and 200--470 μg/ml for methanolic and aqueous extracts respectively \[[@B17]\]. We also demonstrated that they effectively reduced invasion, migration, and adhesion activities of A549 cells in a dose-dependent manner and was capable of inducing apoptosis along with its antimetastastic action \[[@B17]\]. Therefore, the main objective of this study was to determine the protein expression profile of *Phyllanthus*-treated A549 cells and how the signaling pathways were utilized by *Phyllanthus* in order to exert its antiproliferative and antimetastatic activities on this cell line.

Methods
=======

Plant extracts and standard drugs
---------------------------------

The crude extracts (aqueous and methanolic) of each *Phyllanthus spp*., namely *P. niruri*, *P. urinaria*, *P. watsonii* and *P. amarus*, were obtained from the Malaysian Agriculture and Research Development Institute (MARDI), Malaysia. The aqueous extracts were prepared by dissolving 10 mg in 1ml of sterile PBS (Final concentration 10 mg/ml), whereas, the methanolic extracts were prepared by dissolving 40 mg in 1ml of DMSO (Final concentration 40 mg/ml). The tubes containing the extracts were wrapped with aluminium foil and stored at -20°C until use. A single batch of extracts was used for all the experiments. The IC~50~ concentrations that were used as one of the treatment conditions in most of the experimental assays (Table [1](#T1){ref-type="table"}) as well as the polyphenol contents of these extracts have been determined and published in the previous study \[[@B17]\]. Cisplatin and Doxorubicin (MERCK -- 1 mg/ml) as standard anticancer drugs for lung and breast carcinomas respectively were included as the controls.

###### 

**Cytotoxic effect \[IC**~**50**~**(μg/ml)\] of*Phyllanthus*extracts against A549 and MCF-7**

                                                       **IC**~**50**~**(μg/ml) ± SEM**  
  ---------------- --------------------- ------------ --------------------------------- ---------------
   Plant extracts    *P. niruri (P.n)*     Aqueous              466.7 ± 41.63            179.7 ± 0.58
                                          Methanolic            128.3 ± 17.56             62.3 ± 9.07
                    *P. urinaria (P.u)*    Aqueous              215.0 ± 21.79            139.3 ± 1.16
                                          Methanolic            69.0 ± 11.53             48.7 ± 10.02
                    *P. watsonii (P.w)*    Aqueous              198.3 ± 10.41            104.0 ± 10.39
                                          Methanolic            61.3 ± 16.17              49.0 ± 8.19
                     *P. amarus (P.a)*     Aqueous              240.0 ± 26.46            156.7 ± 5.77
                                          Methanolic            126.7 ± 7.64              56.3 ± 6.66

Cell culture
------------

Human lung carcinoma (A549) cell line was purchased from American Type Culture Collection (ATCC, USA) and was grown in RPMI-1640 (Roswell Park Memorial Institute). To ensure growth and viability of the cells, the mediums were supplemented with 10% FBS (Gibco) and incubated in a humidified atmosphere with 5% CO~2~ at 37°C.

Transient transfection and cancer 10-pathway reporter array
-----------------------------------------------------------

Cancer is a group of diseases strongly correlated with defects in signal transduction proteins. Various key signaling pathways have been implicated in human tumorigenesis. Analysis of these signaling pathways was performed using Cignal Finder Cancer 10-pathway Reporter Array kit (SABiosciences, QIAGEN, USA). Transient transfection was performed using TransIT-LT1 (Mirus Bio, USA). Both plasmid DNAs for the respective signaling pathways provided in the kit as well as TransIT-LT1 were diluted using Opti-MEM I reduced serum medium (Invitrogen, USA). After that, plasmid DNAs and the TransIT-LT1 was mixed to allow TransIT-LT1/DNA complex formation. Subsequently, 90 μl (approximately 10000 cells) of the cell suspension were mixed with 10 μl of the complex and added into the designated wells of a 96-well cell culture white microplate (Nunc, Thermo Fisher Scientific, USA). The culture plate was rocked for 5 minutes on a rocker before it was incubated in a 5% CO~2~ incubator at 37ºC overnight. After the transfection of cells with various plasmid DNAs for the respective signaling pathways, the cells were incubated with different *Phyllanthus* extracts for another 24 hours. Dual-Glo Luciferase reagent was then added into each well and incubated at room temperature for 10 minutes before reading the firefly luminescence generated using the GloMax Multi Detection System (Promega, USA). This was followed by the addition of Dual-Glo Stop & Glo reagent to all wells. Similarly, another renilla luminescence reading was obtained after the plate was incubated for another 10 minutes. The firefly constructs monitor changes in the activity of a key transcription factor which is a downstream target of a particular signaling pathway. Meanwhile, renilla construct acts as an internal control for transfection efficiencies normalization as well as to monitor cell viability. Luminescence for each wells were determined by calculating the ratio of its firefly to renilla luminescence.

Cell cycle analysis
-------------------

DNA content analysis is performed by Propidium iodide (PI) staining which binds to the distinct amount of DNA content in the cells at different phases of the cell cycle. Briefly, cells were seeded at 10^5^ cells/well, treated with extracts at their IC~50~ values, and incubated at various time periods from 0 to 72 hours. At the end of each incubation period, cells treated with or without *Phyllanthus* extracts were harvested and fixed with ice-cold 70% ethanol for at least 1 hour at -20ºC. Cells were then pelleted, washed once with PBS, resuspended in the PI solution \[10μg/ml PI (Sigma) and 1mg/ml RNase A in PBS\], and incubated in a 37°C water bath for 30 minutes. Data acquisition was performed using a Becton Dickinson FACSCalibur flow cytometer and CellQuest software and subsequently analysed using WinMDI 2.9 software. The distribution of cell percentages in each cell cycle phase is determined by setting gates based on their amount of DNA content.

Preparation of cytoplasmic protein lysate
-----------------------------------------

Protein lysates were prepared for western blotting and proteomic analysis for both *Phyllanthus*-treated and untreated samples. Cells treated with *Phyllanthus* extracts were detached from the culture plates using 0.5% trypsin-EDTA and washed twice with phosphate buffered saline (PBS), centrifuging at 1500 rpm for 5 minutes. Two hundred microliters of lysis buffer (7M urea, 2M thiourea, 4% CHAPS, 2% IPG buffer, 40 mM DTT) was added to the cell pellet and incubated on ice for 30 minutes before collecting the supernatant into a new 1.5 ml tube followed by addition of 4× sample volume of iced-cold acetone. After that, the sample was incubated at -20°C overnight and centrifuged at 14000 rpm for 15 minutes at 4°C. After centrifugation, the supernatant was discarded while the cytoplasmic protein pellet was diluted in 150 μl of rehydration buffer (7 M urea, 2 M thiourea, 2% CHAPS, 0.5% IPG Buffer, 0.002% bromophenol blue). Cytoplasmic protein lysate was either stored at -80°C for storage or quantified immediately for subsequent experiments.

Western blot assay
------------------

Protein lysate concentration was determined using 2-D Quant kit (GE Healthcare, USA) according to the manufacturer's instructions. For one-dimensional western blotting, thirty micrograms protein of each samples were mixed with 4× sample buffer (50mM Tris-HCl \[pH6.8\], 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5mM EDTA, 0.02% bromophenol blue) before they were loaded on a 12.5% of SDS-polyacrylamide gel. The proteins were separated at 100V for approximately 1 hour. Alternatively, one hundred and fifty micrograms for each protein samples were separated by two-dimensional (2D) gel electrophoresis method using 7 cm IPG gel strips with pH 3--11 NL range (GE Healthcare, USA). After electrophoresis, the stack or sandwich was assembled and the proteins were transferred onto a nitrocellulose membrane (GE Healthcare, USA) at 250 mA for 1 hour. After the transfer, the membrane was blocked with Tris buffered saline buffer consisting 0.1% Tween 20 (TBST) and 5% dry milk. Subsequently, membranes were incubated with various primary antibodies and secondary antibodies diluted using blocking solution. The immune-reacted proteins were detected via chromogenic method by addition of DAB substrate onto the membrane to form a protein band. Anti-pan-Ras, anti-c-Raf, anti-c-Myc, anti-Bcl-2, anti-Hif-1α, anti-c-Jun/AP-1, anti-p53, anti-Elk1, anti-JNK1/2, anti-VEGF, goat anti-mouse IgG peroxidase conjugate, and goat anti-rabbit IgG peroxidase conjugate antibodies were purchased from Merck Millipore, Germany while anti-RSK antibody was purchased from Thermo Fischer Scientific, USA. These antibodies were chosen based on their essential roles in the pathways modulated by *Phyllanthus* as detected using the Cignal Finder Cancer 10-pathway Reporter Array. A p53 antibody was included to determine any involvement of p53 pathway in response to *Phyllanthus* treatment.

Zymography assay
----------------

Zymography is a simple and sensitive technique employed to study extracellular matrix-degrading proteases such as MMPs based on their substrate specificity and molecular weight. Briefly, cells were seeded at 1 × 10^5^ cells/well in a 24-well microtiter plate and treated with increasing concentrations of aqueous (50 μg/ml, IC~50~, 500 μg/ml) and methanolic (20 μg/ml, IC~50~, 200 μg/ml) extracts. After 72 hours incubation, supernatants were collected and stored at -20°C to be used as conditioned media. The conditioned media was mixed with 2× sample buffer (0.5M Tris-HCl \[pH6.8\], 87% glycerol, 10% SDS, 0.1% bromophenol blue) and subsequently loaded onto a 12.5% SDS-polyacrylamide gels that had been copolymerized with 0.1% gelatin or 0.2% casein. The gel was then run at approximately 125V for about 60 minutes. When the proteins were completely resolved, the gel was washed twice with renaturing buffer (2.5% Triton X-100) on a shaker at room temperature, 1 hour for each washing. Next, the gel was incubated with developing buffer (12.1 g Tris, 63 g Tris-HCl, 117 g NaCl, 7.4 g CaCl~2~, 0.2% Brij35, 1L distilled water) overnight at 37°C before it was stained with 0.1% Coomasie blue for 1 hour. Finally, the gel was destained with destaining solution and the presence of matrix metalloproteinase enzyme was indicated as an opaque, unstained band against a dark blue background.

Human total iNOS and GADPH immunoassay
--------------------------------------

Inducible Nitric Oxide Synthase (iNOS) is often upregulated in tumor cells and is an important regulator for vascularization and angiogenesis. In order to measure the total iNOS in whole cell, a cell-based ELISA, Human Total iNOS Immunoassay (R&D Systems, USA) was performed according to the manufacturer's instructions.

2-Dimensional gel electrophoresis
---------------------------------

Five hundred microgram proteins for A549 cells (treated and untreated samples) were rehydrated overnight on 13 cm IPG gel strips with pH 3--11 NL range (GE Healthcare, USA). Strips rehydrated with proteins were then transferred into IPG chambers and focused using Ettan IPGphor Isoelectric Focusing unit (GE Healthcare, USA). Before proceeding with SDS-PAGE, the strips were first subjected to a two-step equilibration procedure for 15 minutes each. Firstly, they were equilibrated with an SDS-PAGE equilibration base buffer added with 2% (w/v) Dithiothreitol (DTT), followed by equilibration with 2.5% (w/v) Iodoacetamide (IAA). The strips were then placed onto a 12.5% SDS-PAGE gel and sealed with agarose sealing solution. Second dimensional separation was carried out using Ettan Dalt*twelve* Separation Unit (GE Healthcare, USA). The gels were then fixed using gel fixative solution and stained with Coomasie dye. Finally, the gel was destained with destaining solution and imaged using Ettan DIGE Imager (GE Healthcare, USA). Three independent gels were run for each treatment (n = 3). Gel images were analyzed using PDQuest 2-D Analysis Software (Bio-Rad, USA) which performed background removal, normalization, and automatic matching of the detected protein spots. Protein spots with more than 2-fold differential expression that showed significant difference (p \< 0.05) were selected and excised for mass spectrometry analysis.

In-gel enzyme digestion
-----------------------

Protein spots excised from gels were first destained using 50% acetonitrile (ACN) in 50 mM ammonium bicarbonate and then incubated with 10mM DTT for 30 minutes at 60°C followed by incubation with 55 mM iodoacetamide for 20 minutes in the dark. The gel plugs were then washed with 50% ACN in 100 mM ammonium bicarbonate before incubation with 100% ACN for 15 min on a shaker and dried using SpeedVac. The dried gel plugs were subsequently incubated with 6 ng/μl trypsin in 50 mM ammonium bicarbonate overnight at 37°C, vortexed briefly and spun down before 50% and 100% ACN were added and shaken for 15 minutes each. The supernatant of each round of extraction was transferred into a fresh tube before the digested samples were completely dried using SpeedVac. The samples can be kept at -20°C until further use. Otherwise, extracted peptides were concentrated or desalted using ZipTip C18 microcolumns (Merck Millipore, Germany).

MALDI-TOF/TOF mass spectrometry and database searching
------------------------------------------------------

Prior to MALDI-TOF/TOF analysis, 3 μl of each extracted peptide sample solution was mixed with 3 μl of alpha-cyano-4-hydroxycinnamic acid (Sigma-Aldrich, USA) matrix solution dissolved in 50% aqueous ACN containing 0.1% trifluoroacetic acid (Sigma-Aldrich, USA). A volume of 0.7 μl of each sample was applied onto a MALDI plate and was allowed to air dry at room temperature. Analysis was performed with ABSCIEX 4800 MALDI-TOF/TOF (AB SCIEX, USA) operated in the reflector for MALDI-TOF/TOF with fully automated mode using the 4800 Series Explorer software at an accelerating voltage of 20 kV. Calibration was performed using Mass Standards Kit for Calibration of AB SCIEX TOF/TOF™ Instruments (AB SCIEX, USA). Data collected from the MALDI-TOF/TOF were submitted to the SwissProt database using the MASCOT search algorithm (version 2.1.0, Matrix Science, London, UK). Typical search parameters for both search engines were defined as follows: trypsin digestion allowing up to two tryptic-mass cleavages, variable modifications of oxidation and carbamidomethyl, maximal mass tolerance of 0.1Da, precursor tolerance of 100 ppm, and taxonomy *Homo sapiens*. Protein scores greater than 55 were considered significant (p \< 0.05). The protein with the highest number of peptides was considered as those corresponding to the spot if multiple proteins were identified in a single spot. The proteins identified were then compared with Uniprot KB/Swiss-Prot database and grouped according to the Eukaryotic Orthologous Group of Classifications (COGs).

Data analysis
-------------

Results were expressed as the mean ± Standard Error Mean (SEM) of data obtained from three independent experiments. All data were analyzed using one way ANOVA, followed by Dunnett's test for pairwise comparison. *P* \< 0.05 was considered statistically significant for all tests.

Results
=======

Determination of signaling pathways affected by *Phyllanthus*
-------------------------------------------------------------

The Cignal Finder Cancer 10-pathway reporter array was used to simultaneous screen 10 main cellular pathways that are targeted by *Phyllanthus* in its anticancer activities. The pathways included in this array include Wnt, Notch, p53/DNA damage, TGFβ, Cell cycle/pRb-E2F, NFκB, Myc/Max, Hypoxia, MAPK/ERK, and MAPK/JNK, with GFP construct plasmid DNA as the positive control for this array. As shown in Figure [1](#F1){ref-type="fig"}A (aqueous extracts-treated A549) and 1B (methanolic extracts-treated A549), the expression of GFP construct was consistent in both the aqueous and methanolic extracts-treated and untreated-control A549 cells, hence the results obtained were deemed valid. Upon treatment with various aqueous and methanolic extracts, most of these pathways' expression \[Myc/Max, Hypoxia, and MAPK (ERK and JNK)\] decreased significantly (*p* \< 0.05) except for NFκB which indicate *Phyllanthus* probably did not modulate this pathway. The aqueous *Phyllanthus* extracts showed better inhibitory activity on the expression of both MAP kinase pathways, while the methanolic extracts showed enhanced inhibition on the expression of Hypoxia and Myc/Max pathways. Among the four plant species, *P. watsonii* exhibited greatest suppression on Hypoxia (aqueous -- 60% and methanolic -- 86%), ERK (aqueous -- 47% and methanolic -- 27%), and JNK (aqueous -- 50% and methanolic -- 26%) pathways, followed by *P. urinaria*, *P. amarus*, and *P. niruri*.

![**Expression level of ten cellular signaling pathways in A549 cells treated with (a) aqueous*Phyllanthus*extracts and (b) methanolic*Phyllanthus*extracts.** Error bar indicates the standard error of the mean of three independent experiments. PN -- *P. niruri*, PU -- *P. urinaria*, PW -- *P. watsonii*, PA -- *P. amarus*. \**P* \< 0.05 vs untreated-control.](1472-6882-13-271-1){#F1}

From the flow cytomery-based cell cycle analysis, we did not observe cell cycle phase arrest in the A549 cells treated with *Phyllanthus* extracts (Figure [2](#F2){ref-type="fig"}) since the percentage of gated cells for each cell cycle phases (G~0~/G~1~, S, and G~2~/M) did not change significantly (*p* \> 0.05) between the untreated and extracts-treated cells. Thus, this further explained the low expression level of cell cycle/pRb-E2F pathway in both the untreated and treated A549 cells. Nevertheless, the percentages decreased with a concurrent increase in the percentage of apoptotic cells (increase in Sub G~1~ phase) at increasing incubation time points (24, 48, and 72 hours). Conversely, there was an accumulation of cells at G~2~/M phase for A549 cells treated with Cisplatin and Doxorubicin.

![**Percentage of cell cycle phase distribution of A549 cells treated with both aqueous and methanolic*Phyllanthus*extracts and standard drugs at their IC**~**50**~**(μg/ml) concentrations for (a) 24 hours, (b) 48 hours, and (c) 72 hours.** Error bar indicates the standard error of the mean of three independent experiments. Aq -- Aqueous, MeOH - Methanolic, Control -- Untreated cells. \**P* \< 0.05 vs untreated-control.](1472-6882-13-271-2){#F2}

Modulation of intracellular signaling molecules expression by *Phyllanthus*
---------------------------------------------------------------------------

In order to confirm the effects of *Phyllanthus* on MAPK and Hypoxia pathways, western blots were performed with available antibodies (Anti-pan-Ras, anti-c-Raf, anti-c-Myc, anti-Bcl-2, anti-Hif-1α, anti-c-Jun/AP-1, anti-p53, anti-Elk1, anti-JNK1/2, anti-VEGF, and anti-RSK) to determine the specific targets of *Phyllanthus*, whether it affects during the early or late stages of the signaling cascade. Figure [3](#F3){ref-type="fig"}A to I showed the blots for untreated A549 control as well as the A549 treated with various aqueous and methanolic extracts while Figure [3](#F3){ref-type="fig"}K depicts the expression level of each protein. In untreated A549, the proteins detected were Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, and HIF-1α. The presence of these proteins reflects the specific involvement of MAPK/ERK and Hypoxia pathways in regulating the A549 cells' growth and survival. In addition, Bcl-2 protein was also detected in untreated A549 which explains its role as an antiapoptotic agent to ensure cell's survival \[[@B27]\]. Besides that, FUSE-binding proteins were also detected although antibody specific to this protein was not included in this experiment. This might probably be attributed to its role for proper regulation of the c-Myc protooncogene \[[@B28]\], as it has a certain percentage of similarity with c-Myc protein and was therefore detected when c-Myc antibody was used. As expected, most of these proteins' expression decreased when A549 was treated with various *Phyllanthus* extracts. Among the four species, *P. urinaria* showed better inhibition on those proteins, followed by *P. amarus*, *P. watsonii*, and *P. niruri* for both the aqueous and methanolic extracts. The expression of Pan-Ras and Elk-1 proteins were only mildly affected as compared to the other proteins and p53 expression was hardly seen in both the treated and untreated A549 cells via western blot technique, thus confirming the findings obtained from the previous cancer 10-pathway array which demonstrated low p53 expression in A549.

![**Expression level of Pan-Ras, c-Raf, c-Jun/AP-1, Elk-1, c-Myc, HIF-1α, Bcl-2, and FUSE-binding proteins in (a) untreated A549 cells and cells treated with (b) aqueous*P. niruri,*(c) aqueous*P. urinaria,*(d) aqueous*P. watsonii,*(e) aqueous*P. amarus,*(f) methanolic*P. niruri,*(g) methanolic*P. urinaria,*(h) methanolic*P. watsonii,*and (i) methanolic*P. amarus*, (j) Expression level of VEGF in untreated-control and*Phyllanthus*-treated A549 cells, (k) Percentage of individual protein expression analysed using Image J software.**](1472-6882-13-271-3){#F3}

Inhibition of matrix metalloproteinases (MMPs) expression by *Phyllanthus*
--------------------------------------------------------------------------

MMPs play an important role during tumor metastasis and angiogenesis since its expression level is often correlated with the tumor invasiveness \[[@B29]\]. Among the variety of MMPs, MMP2, MMP7, and MMP9 were more commonly associated with cancer metastasis as they have the ability to degrade collagen type IV which is the major component of basement membrane \[[@B23],[@B25]\]. MMP7 probably plays a greater role in A549 metastasis since its expression was higher with brighter and clearer bands as compared to MMP2 and MMP9. Nonetheless, their expressions decreased in a dose-dependent manner as shown by the untreated-control and *Phyllanthus*-treated bands' intensity in Figure [4](#F4){ref-type="fig"}. However, the bands for proMMPs with their respective MMPs were not well separated in the zymogram, hence leading to the inability to distinguish between the active and latent MMPs. Methanolic *Phyllanthus* extracts demonstrated greater inhibition on the MMPs' expression than aqueous extracts, with *P. urinaria* showing the greatest inhibitory activity compared to the other *Phyllanthus* species.

![**Matrix metalloproteinases (MMPs) expression level in A549 cells treated with (a and c) aqueous*Phyllanthus*extracts and (b and d) methanolic*Phyllanthus*extracts.** M -- protein marker, C -- untreated control, L -- treatment at 200 μg/ml and 20 μg/ml for aqueous and methanolic extracts respectively, I -- treatment at their respective IC~50~ concentrations, H -- treatment at 500 μg/ml and 50 μg/ml for aqueous and methanolic extracts respectively, PN -- *P. niruri*, PU -- *P. urinaria*, PW -- *P. watsonii*, PA -- *P. amarus*.](1472-6882-13-271-4){#F4}

Inhibition of iNOS and VEGF expression by *Phyllanthus*
-------------------------------------------------------

Angiogenesis or blood vessel formation is the key process in the survival and metastasis of tumors in a hypoxic environment. During hypoxia, cytoplasmic HIF-1α subunit stabilization will lead to the activation of various genes including vascular endothelial growth factor (VEGF) and inducible nitric oxide synthases (iNOS) \[[@B30]\]. This was verified with the high expression of both VEGF and iNOS detected in the untreated-control A549 cells (Figure [5](#F5){ref-type="fig"}) using a cell-based ELISA assay. Upon treatment with various *Phyllanthus*, both the aqueous and methanolic extracts for all four species were observed to demonstrate inhibition on iNOS, whereby most of their expressions dropped markedly to approximately 20% except for methanolic *P. urinaria* which retained 40% of iNOS expression. Generally, *P. urinaria* (78% reduction) scored highest iNOS inhibition among aqueous extracts while *P. watsonii* (82% reduction) exhibited strongest activity among methanolic extracts. This suppression ability was comparable to Cisplatin and Doxorubicin with 15% and 10% iNOS expression that remained after treatment respectively.

![**Expression level of (a) iNOS and (b) VEGF in untreated and*Phyllanthus*-treated A549 cells.** APN - aqueous *P. niruri,* APU - aqueous *P. urinaria,* APW - aqueous *P. watsonii,* APA - aqueous *P. amarus,* MPN - methanolic *P. niruri,* MPU - methanolic *P. urinaria,* MPW - methanolic *P. watsonii,* MPA - methanolic *P. amarus*, CIS -- Cisplatin, DOX -- Doxorubicin. Error bar indicates the standard error of the mean of three independent experiments. *P* \< 0.05 for all extracts-treated A549 compared to untreated-control A549.](1472-6882-13-271-5){#F5}

On the other hand, methanolic *Phyllanthus* extracts showed better suppression of VEGF expression with 60 -- 80% reduction compared to aqueous extracts which caused 20 -- 50% reduction. In addition to this ELISA assay, expression of VEGF was also confirmed by western blot assay when VEGF expression dropped to 30 -- 80% after A549 cells were treated with aqueous and methanolic *Phyllanthus* extracts (Figure [3](#F3){ref-type="fig"}J and K). Among the four species, methanolic *P. amarus* displayed better VEGF repression with only 20% VEGF expression. Meanwhile, *P. urinaria* exhibited slightly weaker capability to inhibit VEGF expression with 25% (aqueous) and 65% (methanolic) reduction respectively.

Differentially expressed proteins in *Phyllanthus*-treated A549
---------------------------------------------------------------

Figure [6](#F6){ref-type="fig"} showed representative 2D-PAGE gels for untreated-control, aqueous *P. watsonii*-treated, and methanolic *P. watsonii*-treated A549 samples. Two-dimensional gel electrophoresis proteomic analysis picked out 68 and 79 protein spots differentially expressed in aqueous and methanolic extracts-treated groups respectively. Subsequent mass spectrometry analysis and database examination using MASCOT identified 52 protein spots significantly downregulated by aqueous *Phyllanthus* extracts as listed in Table [2](#T2){ref-type="table"}. These protein spots were further categorized according to Clusters of Orthologous Groups (COGs) classification and majority of them fell into the category of post-translational modification, protein turnover, and chaperones, followed by intracellular trafficking, secretion, and vesicular transport, cytoskeleton, as well as energy production and conversion (Figure [7](#F7){ref-type="fig"}A). On the other hand, methanolic *Phyllanthus* extracts significantly suppressed 64 proteins as tabulated in Table [3](#T3){ref-type="table"}. Most of these proteins fell into the category of signal transduction mechanisms, transcription, defense mechanisms, amino acid transport and metabolism, as well as secondary metabolites biosynthesis, transport, and catabolism (Figure [7](#F7){ref-type="fig"}B). The negative (-) symbol in both Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} signified suppression of the proteins and a value of 1.00 indicates the complete absence of this protein in the *Phyllanthus*-treated sample as compared to the untreated-control sample and the degree of suppression reduces as the value increases.

![**Representative 2D-PAGE gels for (a and b) untreated-control A549 and its aqueous*P. watsonii*-treated A549, as well as (c and d) untreated-control A549 and its methanolic*P. watsonii*-treated A549.**](1472-6882-13-271-6){#F6}

###### 

**Identified proteins of A549 downregulated (-) in the presence of aqueous*Phyllanthus*extracts**

   **Spot ID**                         **Possible proteins**                         **Fold change**   **UNIPROT KB/SWISS-PROT Acc. Number**   **Database**                   
  ------------- ------------------------------------------------------------------- ----------------- --------------------------------------- -------------- ------- -------- -----------------------------------
        1                              Actin, cytoplasmic 1                               -0.81                        -0.88                      -0.95       -0.84   P60709   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        2                        Nicotinamide N-methyltransferase                         -0.50                         N/A                       -0.28       -0.10   P40261   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        3                                  Alpha-Enolase                                  -0.62                        -0.57                      -0.48       -0.58   P06733   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        4                         Proteasome subunit beta type 3                          -1.00                        -0.20                       N/A        -1.00   P49720   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        5                             Retinal dehydrogenase 1                             -0.23                         N/A                       -0.13        N/A    P00352   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        6                                   Galectin-1                                    -1.00                        -0.13                      -0.57       -0.38   P09382   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        7                            Heat-shock protein beta-1                            -0.12                        -0.22                      -0.32       -0.10   P04792   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        8                    Glyceraldehyde-3-phosphate dehydrogenase                     -0.30                        -0.93                      -0.99       -0.91   P04406   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        9                  Eukaryotic translation initiation factor 5A-1                  -0.32                        -0.39                      -0.27       -0.80   P63241   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       10               60 kDa heat shock protein, mitochondrial precursor                -0.46                        -0.82                      -0.90       -0.75   P10809   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       11                         Glutathione transferase omega-1                          N/A                         -0.45                       N/A        -0.22   P78417   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       12                     Proteasome activator complex subunit 1                      -0.19                        -0.18                       N/A        -1.00   Q06323   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       13                                   Annexin A4                                    -0.29                        -0.29                      -0.21       -0.65   P09525   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       14                                    Vimentin                                     -0.91                        -0.82                      -0.24       -0.79   P08670   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       15                      Peptidyl-prolyl cis-trans isomerase A                      -0.13                        -0.36                      -1.00       -0.42   P62937   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       16                      Peptidyl-prolyl cis-trans isomerase A                      -1.00                        -1.00                      -0.32        N/A    P62937   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       17                    Glyceraldehyde-3-phosphate dehydrogenase                     -1.00                        -0.50                      -1.00       -0.71   P04406   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       18               Voltage-dependent anion-selective channel protein 1               -0.37                        -0.19                      -0.20        N/A    P21796   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       19                              Tubulin alpha-8 chain                              -0.80                        -0.37                       N/A        -0.80   Q9NY65   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       20                            Protein FAM24B precursor                             -0.51                        -0.54                      -0.66       -0.88   Q8N5W8   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       21                          Interferon alpha-6 precursor                           -0.41                         N/A                       -0.38       -0.75   P05013   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       22                          ATP-dependent DNA helicase Q5                          -1.00                        -1.00                      -0.93       -0.79   O94762   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       23                                 Sorting nexin-3                                 -0.25                        -1.00                      -1.00       -1.00   O60493   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       24                           Gap junction beta-5 protein                           -0.36                        -0.16                      -0.32       -0.41   O95377   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       25                            40S ribosomal protein S19                            -0.30                        -0.30                      -0.15       -0.38   P39019   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       26                   Stress-70 protein, mitochondrial precursor                    -0.19                        -0.22                       N/A         N/A    P38646   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       27                   Actin-related protein 2/3 complex subunit 5                   -1.00                        -1.00                      -1.00       -1.00   O15511   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       28                                 Sorting nexin-3                                 -0.36                        -0.35                      -0.37       -1.00   O60493   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       29                      Complement receptor type 1 precursor                       -0.19                         N/A                       -0.41       -1.00   P17927   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       30                            40S ribosomal protein S24                            -1.00                        -1.00                      -1.00       -1.00   P62847   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       31                       Corticotropin-lipotropin precursor                        -0.73                        -0.88                      -1.00       -1.00   P01189   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       32                      Inosine triphosphate pyrophosphatase                       -1.00                        -0.67                      -1.00       -1.00   Q9BY32   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       33                                 Peroxiredoxin-1                                 -0.08                        -0.56                      -1.00       -0.33   Q06830   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       34                                  Protein memo                                   -0.95                        -0.88                      -0.56       -0.47   Q9Y316   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       35               Voltage-dependent anion-selective channel protein 2               -1.00                        -0.31                      -0.46       -0.21   P45880   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       36        Thioredoxin-dependent peroxide reductase, mitochondrial precursor        -0.28                        -0.19                      -0.27        N/A    P30048   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       37                                   RuvB-like 2                                   -0.24                         N/A                       -0.43       -0.11   Q9Y230   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       38                       EF-hand domain-containing protein 2                       -0.36                        -0.17                      -0.37       -0.29   Q5JST6   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       39                       T-complex protein 1 subunit epsilon                       -0.89                         N/A                       -0.20       -0.97   P48643   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       40                         Stress-induced-phosphoprotein 1                         -0.54                        -0.62                      -0.44       -0.21   P31948   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       41                             Retinal dehydrogenase 1                             -0.33                        -0.79                      -0.58       -0.61   P00352   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       42                           Prostaglandin E synthase 3                            -0.26                        -0.36                      -0.97       -0.16   Q15185   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       43                               Trypsin-1 precursor                               -0.37                        -1.00                      -0.28       -0.35   P07477   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       44                                    Serpin B9                                    -0.51                        -0.14                      -0.21       -0.51   P50453   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       45                     N-acylneuraminate cytidylyltransferase                      -0.64                        -0.57                      -0.50       -0.28   Q8NFW8   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       46                                    Cofilin-1                                    -0.76                         N/A                       -0.85       -0.38   P23528   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       47                            ADP-ribosylation factor 1                            -1.00                        -0.21                      -0.15       -1.00   P84077   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       48                        Fructose-bisphosphate aldolase A                         -1.00                        -1.00                      -1.00       -1.00   P04075   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       49                                 Sorting nexin-3                                 -1.00                        -1.00                      -1.00       -1.00   O60493   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       50                            Phosphoglycerate mutase 1                            -1.00                        -1.00                      -1.00       -1.00   P18669   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       51                            Triosephosphate isomerase                            -1.00                        -1.00                      -1.00       -1.00   P60174   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       52                  Eukaryotic translation initiation factor 5A-1                  -1.00                        -1.00                      -1.00       -1.00   P63241   MASCOT;UNIPROT KB/SWISS-PROT;COGS

The negative (-) symbol signified suppression of the proteins and a value of 1.00 indicates the complete absence of this protein in the aqueous *Phyllanthus*-treated sample as compared to the untreated-control sample and the degree of suppression reduces as the value increases. APN -- Aqueous *P. niruri*, APU -- Aqueous *P. urinaria*, APW -- Aqueous *P. watsonii*, APA -- Aqueous *P. amarus,* N/A -- Not Affected.

![**Clusters of Orthologous Groups (COGs) classification of identified proteins in A549 cells treated with (a) aqueous*Phyllanthus*extracts and (b) methanolic*Phyllanthus*extracts.**](1472-6882-13-271-7){#F7}

###### 

**Identified proteins of A549 downregulated (-) in the presence of methanolic*Phyllanthus*extracts**

   **Spot ID**                           **Possible proteins**                            **Fold change**   **UNIPROT KB/SWISS-PROT Acc. Number**   **Database**                   
  ------------- ------------------------------------------------------------------------ ----------------- --------------------------------------- -------------- ------- -------- -----------------------------------
        1                                   Protein S100-A8                                    -0.47                        -0.10                      -0.48       -0.55   P05109   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        2                               Transmembrane protein 35                               -0.82                        -0.78                      -1.00       -0.50   Q53FP2   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        3                             Adenylate kinase isoenzyme 6                             -0.32                        -0.62                      -0.81       -0.73   Q9Y3D8   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        4                                   Peroxiredoxin-1                                    -0.78                        -1.00                      -1.00       -1.00   Q06830   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        5                        Prolactin-releasing peptide precursor                         -0.59                        -0.29                      -0.23       -0.39   P81277   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        6                                Putative protein SSX6                                 -0.46                        -0.96                      -1.00       -0.75   Q7RTT6   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        7                                Glutathione synthetase                                -0.38                        -0.79                      -1.00       -0.51   P48637   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        8                   Nucleoside diphosphate-linked moiety X motif 16                    -0.61                        -0.63                      -0.98       -0.94   Q3MHX9   MASCOT;UNIPROT KB/SWISS-PROT;COGS
        9                          E3 ubiquitin-protein ligase ZNRF1                            N/A                          N/A                       -0.47       -0.36   Q8ND25   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       10                  DNA-directed RNA polymerase II 16 kDa polypeptide                   -0.46                        -0.59                      -0.43       -0.93   Q9VEA5   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       11                  39S ribosomal protein L40, mitochondrial precursor                  -1.00                        -1.00                      -1.00       -1.00   Q9NQ50   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       12                               Zinc finger protein 174                                -1.00                        -1.00                      -1.00       -1.00   Q15697   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       13                  Probable G-protein coupled receptor 179 precursor                   -0.21                        -0.15                      -1.00        N/A    Q6PRD1   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       14                                 Histatin-1 precursor                                 -0.24                        -0.66                      -0.78       -0.27   P15515   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       15                       U6 snRNA-associated Sm-like protein LSm5                       -0.33                        -0.57                      -0.19       -0.54   Q9Y4Y9   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       16                                Bcl-2-like protein 11                                 -0.25                        -1.00                      -1.00       -0.70   O43521   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       17                                Contactin-2 precursor                                 -0.29                        -0.60                      -0.42       -0.39   Q02246   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       18                           Bis(5′-adenosyl)-triphosphatase                            -1.00                        -1.00                       N/A        -1.00   P49789   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       19                                 Trypsin-1 precursor                                  -1.00                        -0.98                      -1.00       -1.00   P07477   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       20                          Proliferating cell nuclear antigen                          -1.00                        -1.00                      -1.00       -1.00   P12004   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       21                                Endoplasmin precursor                                  N/A                         -1.00                      -1.00       -0.37   P14625   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       22                Eukaryotic translation initiation factor 3 subunit 12                 -1.00                        -1.00                      -1.00       -1.00   Q9UBQ5   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       23                          Serine/threonine-protein kinase 6                           -1.00                        -0.96                      -0.19       -1.00   O14965   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       24                       Phenylalanyl-tRNA synthetase beta chain                        -1.00                        -1.00                      -1.00       -1.00   Q9NSD9   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       25                           Neutrophil defensin 1 precursor                            -0.78                        -0.49                      -0.20       -0.88   P59665   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       26                        Proto-oncogene protein Wnt-3 precursor                        -0.58                         N/A                       -0.34       -0.55   P56703   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       27                         Putative Ras-related protein Rab-42                          -1.00                         N/A                       -0.97       -0.80   Q8N4Z0   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       28                               UPF0404 protein C11orf59                               -0.19                        -0.36                       N/A        -0.36   Q6IAA8   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       29                           Neutrophil defensin 1 precursor                            -0.31                        -0.25                      -1.00       -0.87   P59665   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       30                          Agouti-signaling protein precursor                          -0.33                        -0.67                      -0.67        N/A    P42127   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       31                  DNA-directed RNA polymerase II 16 kDa polypeptide                   -0.42                        -0.48                      -0.48       -0.45   Q9VEA5   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       32                             Beta-defensin 107A precursor                             -0.21                         N/A                       -0.62       -0.61   Q8IZN7   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       33                   Transcription elongation factor B polypeptide 1                    -0.58                        -0.59                      -0.56       -0.79   Q15369   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       34                                  Metallothionein-1M                                  -0.55                        -0.52                      -0.48       -0.48   Q8N339   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       35                                GTPase HRas precursor                                 -0.60                        -0.66                      -0.59       -0.61   P01112   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       36                                Neuromedin-B precursor                                -0.24                        -0.32                      -0.23       -0.34   P08949   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       37                         Protein-tyrosine sulfotransferase 2                          -0.36                         N/A                        N/A        -0.33   O60704   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       38                            Apolipoprotein A-II precursor                             -0.23                        -0.23                      -0.13       -0.37   P02652   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       39                        ADP-ribosylation factor-like protein 6                        -0.58                        -0.52                      -1.00       -0.29   Q9H0F7   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       40                                    Alpha-enolase                                     -0.27                        -0.51                       N/A        -0.56   P06733   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       41           Serine/threonine-protein phosphatase PP1-beta catalytic subunit            -1.00                        -1.00                      -0.44       -0.71   P62140   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       42                        N-acylneuraminate cytidylyltransferase                        -1.00                        -1.00                      -1.00       -1.00   Q8NFW8   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       43                         Inosine triphosphate pyrophosphatase                         -1.00                        -1.00                      -1.00       -1.00   Q9BY32   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       44                       Alkyldihydroxyacetonephosphate synthase                        -1.00                        -0.55                      -1.00       -1.00   O00116   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       45                      Microsomal signal peptidase 18 kDa subunit                      -1.00                        -0.57                      -1.00       -1.00   P67812   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       46                             Tumor suppressor candidate 2                             -0.89                        -0.75                      -0.67       -0.21   O75896   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       47                                  Metallothionein-2                                   -0.71                        -0.17                      -0.14       -0.53   P02795   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       48                               Protein FAM3B precursor                                -0.57                        -0.48                      -0.39       -0.48   P58499   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       49                                  Metallothionein-1H                                  -0.52                        -0.48                       N/A        -0.29   P80294   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       50                                  Metallothionein-2                                   -0.34                        -0.59                      -0.49       -1.00   P02795   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       51                                     Protein BEX5                                     -0.48                        -0.33                      -0.30       -0.48   Q5H9J7   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       52                  DNA-directed RNA polymerase II 16 kDa polypeptide                   -1.00                        -1.00                      -1.00       -1.00   Q9VEA5   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       53         Cytochrome c oxidase polypeptide VIa-liver, mitochondrial precursor          -0.93                        -0.24                      -1.00       -0.14   P12074   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       54                               Putative protein 15E1.2                                 N/A                         -0.94                      -1.00       -0.30     \-                MASCOT;COGS
       55                 Voltage-dependent anion-selective channel protein 1                  -0.15                        -0.28                      -0.35       -0.27   P21796   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       56                 Voltage-dependent anion-selective channel protein 1                  -0.47                        -0.13                      -1.32        N/A    P21796   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       57           Serine/threonine-protein phosphatase PP1-alpha catalytic subunit           -0.64                        -0.76                      -0.43       -0.32   P62136   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       58                       Acetyl-CoA acetyltransferase, cytosolic                        -0.95                        -1.00                      -0.17       -1.00   Q9BWD1   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       59                                Glutathione synthetase                                -0.50                        -0.45                      -0.38       -0.61   P48637   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       60                               Actin-related protein 10                               -0.94                        -0.70                      -0.13       -0.73   Q9NZ32   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       61                              Enteropeptidase precursor                               -0.63                        -0.19                      -1.00       -0.70   P98073   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       62                                  Metallothionein-1L                                  -0.86                        -0.79                      -0.96       -0.44   Q93083   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       63        Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-5-like subunit        -1.00                        -1.00                      -1.00       -1.00   P63218   MASCOT;UNIPROT KB/SWISS-PROT;COGS
       64                        Small inducible cytokine B14 precursor                        -1.00                        -1.00                      -1.00       -1.00   O95715   MASCOT;UNIPROT KB/SWISS-PROT;COGS

The negative (-) symbol signified suppression of the proteins and a value of 1.00 indicates the complete absence of this protein in the methanolic *Phyllanthus*-treated sample as compared to the untreated-control sample and the degree of suppression reduces as the value increases. MPN -- Methanolic *P. niruri*, MPU -- Methanolic *P. urinaria*, MPW -- Methanolic *P. watsonii*, MPA -- Methanolic *P. amarus,* N/A -- Not Affected.

Discussion
==========

Numerous reports describe poor therapeutic efficacy and prognostic survival for lung malignancy which is largely due to its capability to invade, metastasize, as well as to induce angiogenesis. Therefore, it is crucial to develop novel antimetastatic drugs with low toxicity and high efficacy \[[@B17],[@B29]\]. In our previous study, aqueous and methanolic extracts of *Phyllanthus* was shown to possess the potential to inhibit growth of A549 in a time- and dose-dependent manner with minimal toxicity to the normal lung epithelial (NL20) cells. Besides that, *Phyllanthus* suppressed the invasion, migration, and reattachment of A549 in a dose-dependent manner and was capable of inducing apoptosis in conjunction with its antimetastastic action \[[@B17]\]. However, the underlying mechanisms that confer their antimetastatic and apoptosis-inducing abilities were uncertain.

In the current study, numerous differentially expressed proteins were being identified in A549 cells in response to *Phyllanthus* treatments using 2DE-based proteomic approach. Both aqueous and methanolic *Phyllanthus* extracts modulate expression of different set of proteins \[[@B17]\]. Among the four *Phyllanthus* species, *P. urinaria* generally demonstrated the greatest activity on A549, closely followed by *P. watsonii*, *P. amarus*, and *P. niruri*. This could be delineated by the higher number of polyphenol compounds present in both the aqueous (9 out of 10 polyphenols) and methanolic (3 out of 4 polyphenols) *P. urinaria* extracts \[[@B17],[@B20]\], hence having a higher capability to cause antimetastatic activities on A549. Some of those proteins were represented by more than one spot, which represents different splicing forms of the same protein as a result of post-translational modification \[[@B14]\].

Therefore, protein turnover, chaperones, and post-translational modification are indeed crucial to produce many variants of the common amino acid that possess distinctive structures and functions essential for tumor growth \[[@B31],[@B32]\]. In order to ensure uninterrupted cell growth, continuous protein synthesis is necessary. Therefore, 40S ribosomal protein is normally upregulated in the tumor cell as it is an essential component of the higher eukaryotic ribosome that is necessary for proper protein translational function \[[@B33]\]. Eukaryotic translation initiation factor 3 subunit 12 is another important component as it binds to poly(A)-binding protein to initiate translation process \[[@B34]\]. Protein folding is the subsequent critical process upon successful protein translation to ensure formation of functional proteins and this step usually requires the presence of chaperone proteins. One of these proteins is Hsp60 whose primary role is to guide the folding of mitochondrial proteins while facilitating proteolytic degradation of denatured or misfolded proteins in an ATP-dependent manner \[[@B35]\]. Other chaperones include peptidyl-prolyl cis-trans isomerase A and T-complex protein 1 subunit epsilon which also assists the proper folding of proteins \[[@B36],[@B37]\].

Besides facilitating protein folding, chaperones also guide the proper assembly of other proteins for them to carry out their activities. An important example is stress-induced phosphoprotein 1 that facilitates association of molecular chaperones Hsp70 and Hsp 90 which have been implicated in MMP2 activity that lead to increased invasiveness \[[@B38]\]. Downregulation of these proteins by *Phyllanthus* is therefore one of the key processes for A549 growth and metastasis inhibition by reducing functional protein synthesis and suppression of MMP expression. In addition to MMP2, suppression of other MMPs in response to *Phyllanthus* treatment was also observed including MMP7 and MMP9. Tumor invasion and metastasis depends largely on the integrity of the basement membrane which is frequently destroyed by a number of proteolytic enzymes such as MMPs in order to access the vasculature to develop distant metastases \[[@B22]\]. Among the MMPs family, MMP2 and MMP9 were more commonly associated with cancer invasion and metastasis since they had been known to be able to degrade type IV collagen-rich basement membrane of vessel wall \[[@B23]\]. MMP7 (28 kDa) is another member of the MMP family with broad substrate specificity against ECM components such as elastin, type IV collagen, fibronectin, vitronectin, aggrecan, and proteoglycans \[[@B25]\]. Reduced expression of these MMP enzymes explains the decreased aggressiveness of A549 cells' invasion upon treatment with *Phyllanthus*.

A constant activation of various growth-promoting signaling pathways is also required to ensure continuous cell growth and survival. This activation often involves numerous proteins which require some form of modifications such as phosphorylation for their biological role. Thus, post-translational modification process that alters the proteins properties is important \[[@B39],[@B40]\]. The first step for pathway activation often requires the presence of receptor molecules on the cell surface for ligand binding. So, guanine nucleotide-binding protein, putative Ras-related protein Rab-42, and GTPase HRas precursor protein which can be broadly grouped as G-proteins, as well as probable G-protein coupled receptor 179 precursor expressions are usually elevated in the tumor cells to accommodate the large amount of extracellular signals to be transduced into the cells \[[@B41]\]. Both G-protein coupled receptor and G-proteins form the G-protein mediated signaling cascade whereby binding of ligands to receptors will lead to activation of G-proteins by promoting GDP/GTP exchange, which in turn regulates many effector molecules such as proteins kinases \[[@B41]\]. Therefore, the subsequent upregulated protein in the tumor cell is serine/threonine-protein kinase 6 which is a family of kinases including MAP kinase \[[@B42]\], which functions to turn on the downstream kinases via serine/threonine phosphorylation \[[@B43]\]. Suppression of these cell signaling proteins by *Phyllanthus* could therefore decelerate or stop the constitutive activation of the growth-promoting pathways such as MAP kinase and hypoxia.

ERK1/2 pathway is one of the MAP kinase subgroup which was frequently found to be inhibited in A549 to repress cells' continuous growth and metastasis. In a study by Shih et al. \[[@B21]\], α-tomatine found in tomatoes was shown to be capable of inactivating extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway to inhibit metastasis occurrence in A549 cell line. Similarly, A549 metastasis was also inhibited by Silibinin isolated from *Silybum marianum* which suppresses ERK1/2 pathway that led to a reduced expression of MMP2 and u-PA concomitantly with a significant inhibition on cell invasion \[[@B22]\]. Indeed, our study also showed that *Phyllanthus* inhibit A549 metastasis via targeting specifically ERK1/2 pathway. ERK1/2 module is often thought as a linear pathway since ERK is the effector of an evolutionarily conserved signaling component that is triggered exclusively by the Raf serine/threonine kinases \[[@B44],[@B45]\]. Therefore, *Phyllanthus* might possibly downregulate Raf protein at the early stage of the pathway, resulting in the subsequent suppression of other proteins' expression down the pathway. As a result, various biological activities controlled by ERK1/2 pathway to increase cell growth and malignancy are repressed, including regulation of transcriptional, cell cycle, apoptosis, and metastasis \[[@B46]\].

Transcription is an important biological activity in a cell as it is the first step for the transmission of genetic information from DNA into RNA to be translated into proteins \[[@B47]\]. With the suppression of the essential transcriptional proteins for eukaryotic chromosomal DNA replication such as DNA-directed RNA polymerase II 16kDa polypeptide, transcription elongation factor B polypeptide 1, and proliferating cell nuclear antigen, transcription initiation and elongation process becomes inefficient \[[@B48],[@B49]\]. Besides that, zinc finger protein 174 is a DNA binding protein that acts as a cofactor for transcription factor. Its downregulation will lead to increased transcription of proteins such as E-cadherin which in turn represses cell invasion \[[@B50]\]. Also, cell cycle disorder plays a critical role in cancer progression. So, modulation of cell cycle by phytochemicals from natural product sources is gaining worldwide attention to control carcinogenesis \[[@B51]\]. However, our findings showed that cell cycle pathway was not modulated with the flow cytometric data showing insignificant shifts in each cell cycle phases for the cells treated with *Phyllanthus* extracts. Hence, cell cycle arrest was ruled out as one of the mechanism of actions of the extracts. Since *Phyllanthus* do not inflict cell cycle arrest on A549, the only approach to inhibit A549′s continuous growth is by causing toxicity. As showed in the previous study, *Phyllanthus* does induce apoptosis in A549 with more than three folds increase of caspases-3 and -7, the presence of DNA-fragmentation and TUNEL-positive cells \[[@B17]\]. In order to determine whether *Phyllanthus* induces extrinsic or intrinsic apoptotic pathway, Bcl-2 expression was examined using immunoblot analysis since it is one of the main regulators of the mitochondrial outer membrane permeabilization which initiates intrinsic apoptotic cell death \[[@B52],[@B53]\]. The data obtained agrees with our previous hypothesis that *Phyllanthus* probably activates the intrinsic pathway of apoptosis by inhibiting antiapoptotic Bcl-2 protein to release cytochrome c for caspases activation. In addition to this, proteomic analysis also observed downregulation of Bcl-2-like protein 11 which is similar to Bcl-2 protein that has a role as an antiapoptotic protein \[[@B52]\]. Apart from that, suppressing MAP kinases and its downstream factors such as AP-1 have been shown to decrease MMPs expression and subsequently inhibit various pathological processes such as tumor invasion, adhesion, metastasis, and angiogenesis \[[@B22],[@B24]\]. This is in accordance with results from the current study that showed decreased ERK1/2 pathway and MMPs activity by *Phyllanthus* which led to inhibition of A549 metastasis. Moreover, *Phyllanthus* extracts also suppressed cytoskeletal proteins such as actin, vimentin, tubulin alpha chain, actin-related protein, and cofilin-1/2. Besides being the components of the cytoskeleton, both actin and tubulin-binding proteins are also mediators of motility \[[@B8]\]. Structure, conformational dynamics, and mechanical properties of actin filaments are mainly controlled by cofilin \[[@B54]\]. Meanwhile, vimentin constitutes the intermediate filaments of the cytoskeleton which stabilizes cytoskeletal interactions as well as affecting cell motility and movement. Elevated expression of vimentin in several invasive cell lines suggests the possibility of it being a representative marker for epithelial to mesenchymal transition \[[@B38]\]. Therefore, the significant inhibitory effects of *Phyllanthus* on the A549 cell's cytoskeleton most probably involve the alteration of the microfilament organization and function, therefore suppressing motility and metastasis \[[@B55]\].

Hypoxia is largely perceived as another major obstacle to cancer therapy as increasing evidence in the cancer therapy-related literatures suggests the involvement of proangiogenic factors in the progression of lung tumorigenesis \[[@B7]\]. Angiogenesis is essential for tumor growth and survival due to the imbalance of nutrient and oxygen supplies to solid tumors larger than 1 mm^3^, resulting in tumor hypoxia \[[@B56]\]. One of the major regulatory component which responds to hypoxia to ensure cell survival and to promote angiogenesis is HIF-1α \[[@B2],[@B7]\]. Therefore, it could possibly be the target for the development of novel anticancer agents. Lin et al. \[[@B7]\] demonstrated suppression of lung tumor angiogenesis and metastasis by andrographolide isolated from *Andrographis paniculata* which downregulates HIF-1α. In addition, inhibition of HIF-1α pathway by *HIF-1α--siRNA* displayed a direct correlation with A549 cellular proliferation and angiogenesis, a prerequisite for metastasis \[[@B26]\]. In agreement to these studies, our results obtained also showed the reduction of HIF-1α expression in A549 cells treated with *Phyllanthus* extracts. This in turn led to the suppression of various target genes controlled by HIF-1α via hypoxia-responsive-element (HRE) \[[@B26]\], including angiogenesis, metabolism, cell growth, and death \[[@B2]\].

VEGF is another crucial angiogenic growth factor which induces endothelial cell proliferation from the pre-existing capillary bed for wound healing, tumor growth, and metastasis. Its expression is therefore increased prior to an invasive and metastatic phenotype \[[@B56]\]. Also iNOS, one of the three distinct isoforms of NOS which is widely expressed and often upregulated in multiple tumor tissues \[[@B57]\] is expressed in tumor cells associated with vascularization and hence, is probably another important regulator of angiogenesis \[[@B56],[@B57]\]. Nitric oxide (NO) produced by NOS have been shown to affect vascular permeability, induce extracellular matrix degradation, trigger VEGF production, as well as stimulate endothelial cell proliferation and migration \[[@B30]\]. Hence, inhibition of VEGF and iNOS by *Phyllanthus* can greatly reduce A549 angiogenesis, resulting in tumor cells malnutrition and hypoxia thereby preventing tumor growth, survival, and metastasis. Adenosine 5′-triphosphate, a major source of energy for cells and its involvement in a variety of cellular activities which are ATP-dependent is often increased in tumor cells \[[@B58]\]. Downregulation of these enzymes activities by *Phyllanthus* causes cellular energy deficit that can result in cancer cell death. One example is enolase which catalyzes conversion of 2-phosphoglyceric acid (PGA) to phosphoenolpyruvate (PEP) in the anabolic pathway during gluconeogenesis to enhance aerobic glycolysis in cancer cells \[[@B59]\]. Other enzymes suppressed include glyceraldehyde 3 phosphate dehydrogenase, fructose-biphosphate aldolase A, phosphoglycerate mutase 1, and triosephosphate isomerase that are also involved in energy metabolism \[[@B55],[@B60]\].

Besides exploiting cellular signaling pathways for their growth and metastasis, tumor cells possess efficient drug detoxification system to remove compounds that may be fatal to them. This includes upregulation of glutathione transferase omega-1 that catalyzes binding of glutathione to various anticancer compounds such as cisplatin, thereby decreasing production of platinum-DNA adducts and rendering them useless while glutathione synthetase catalyzes production of glutathione substrate for the detoxifying activity \[[@B61],[@B62]\]. Similarly, metallothionein also plays a role in chemotherapy binding and detoxification since its elevated expression was noticed in several cisplatin-resistant lung cancer cell lines \[[@B61]\]. Meanwhile, Annexin A4 is normally associated with chemoresistance in part by enhancing drug efflux \[[@B63]\]. Inhibition of these detoxification enzymes expressions in A549 after treatment with *Phyllanthus* as demonstrated from the proteomic analysis therefore advocates the reduced A549 drug-resistance capability resulting in their susceptibility to death-inducing compounds.

Conclusions
===========

All the findings obtained in this study point to the involvement of ERK1/2 and hypoxia pathways which were suppressed by *Phyllanthus* to inhibit A549 proliferation, angiogenesis, invasion, and metastasis. Inhibition of ERK1/2 pathway led to downregulation of invasion and mobility proteins (MMP2; MMP7; MMP9; cytoskeletal proteins), transcriptional proteins (proliferating cell nuclear antigen; zinc finger protein), and antiapoptotic protein (Bcl2) while inhibition of hypoxia pathway causes repression of angiogenic proteins (VEGF; iNOS) and various glycolytic enzymes. Suppression of drug detoxification enzymes such as gluthathione transferase and metallothionein also increases sensitivity of A549 to *Phyllanthus* treatment. Among the four *Phyllanthus* species tested in this study, *P. urinaria* was found to be the most effective to inhibit A549 growth and metastasis, closely followed by *P. watsonii*. Thus, *Phyllanthus* could be a valuable candidate in the treatment of metastatic cancers. However, the main concern before application of *Phyllanthus* as an antimetastatic or antiproliferative agent is its *in vivo* effect. Thus, further testing of the extracts activity *in vivo* is necessary to exploit it as a chemotherapeutic agent. Preliminary work has identified low toxicity of *Phyllanthus* in an animal model as dosage greater than 50 g/kg is needed to cause 100% acute death in the mice tested (unpublished data) and subsequent efficacy testing in a tumor-bearing mice model needs to be carried out.
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